Ankyra Therapeutics targets a bigger immunotherapy problem with anchored monoclonal antibodies
Cancer antibodies can be powerful but toxic. Ankyra’s anchored platform asks whether local retention can widen immunotherapy’s safety window.
Cancer antibodies can be powerful but toxic. Ankyra’s anchored platform asks whether local retention can widen immunotherapy’s safety window.